Korea UCB Pharma said on the 12th that it appointed Edward Lee as the new head.
UCB Pharma is a Belgium-headquartered pharmaceutical company specializing in neurological and immunology diseases, and it recently received domestic approval for the plaque psoriasis treatment "Bimzelx" and the generalized myasthenia gravis treatments "Zilbrysq" and "Rystiggo." The treatment for Dravet syndrome, a rare and intractable pediatric epilepsy, was designated in May 2024 as item No. 30 under the Ministry of Food and Drug Safety's Global Innovative product Framework (GIFT).
Head Lee has more than 15 years of experience in market access, medical affairs, and health economics and outcomes research (HEOR) in the global pharmaceutical industry. Since joining UCB in 2016, Lee has held key roles at the U.S. and U.K. affiliates and the Intercontinental headquarters, and most recently oversaw patient access, sustainability, and external affairs. Before that, Lee led new drug value assessment and patient access projects at Japan's Astellas and C. H. Boehringer Sohn AG & Co. KG in Germany.
Lee earned a Doctor of Pharmacy degree from the University of Illinois Chicago and completed an HEOR program through a joint fellowship between Thomas Jefferson University and Japan's Daiichi Sankyo. Lee said, "Korea UCB Pharma will enhance access to innovative therapies with a patient-centered approach, and we will strengthen collaboration in new drug approvals and reimbursement so that domestic patients can quickly receive the benefits of treatment."